What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Sell
43
HLN Quote, Financials, Valuation and Earnings
Last price:
$10.05
Seasonality move
:
1.35%
Day range:
$9.41 - $9.71
52-week range:
$7.99 - $10.80
Dividend yield:
1.64%
P/E ratio:
23.94x
P/S ratio:
3.08x
P/B ratio:
2.14x
Volume:
20.5M
Avg. volume:
12.1M
1-year change:
17.87%
Market cap:
$43.5B
Revenue:
$14.4B
EPS (TTM):
$0.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLN
Haleon PLC
|
$3.7B | $0.32 | 0.78% | 8.98% | $10.71 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$7M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
AZN
AstraZeneca PLC
|
$13.7B | $1.11 | 8.23% | 83.1% | $85.68 |
|
GSK
GSK PLC
|
$9.6B | $0.98 | 3.46% | 52.75% | $43.55 |
|
PFE
Pfizer
|
$14.3B | $0.70 | -3.4% | 31.46% | $30.73 |
|
SNN
Smith & Nephew PLC
|
$1.4B | -- | -- | -- | $32.14 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLN
Haleon PLC
|
$9.63 | $10.71 | $43.5B | 23.94x | $0.05 | 1.64% | 3.08x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.22 | $1.71 | $55.3M | -- | $0.00 | 0% | 0.31x |
|
AZN
AstraZeneca PLC
|
$64.87 | $85.68 | $201.1B | 28.77x | $1.05 | 2.39% | 3.75x |
|
GSK
GSK PLC
|
$33.60 | $43.55 | $68.5B | 21.22x | $0.40 | 4.63% | 1.73x |
|
PFE
Pfizer
|
$21.59 | $30.73 | $122.4B | 15.31x | $0.43 | 7.83% | 1.93x |
|
SNN
Smith & Nephew PLC
|
$25.05 | $32.14 | $10.9B | 26.65x | $0.46 | 2.99% | 1.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLN
Haleon PLC
|
38.17% | 0.075 | 28.98% | 0.75x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 4.133 | 36.44% | 2.60x |
|
AZN
AstraZeneca PLC
|
41.27% | -0.160 | -- | 0.74x |
|
GSK
GSK PLC
|
53.74% | -0.068 | 29.19% | 0.49x |
|
PFE
Pfizer
|
41.92% | 0.587 | 43.87% | 0.82x |
|
SNN
Smith & Nephew PLC
|
37.25% | 0.641 | 29.11% | 1.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLN
Haleon PLC
|
$2B | $448.1M | 5.64% | 8.91% | 14.46% | $921M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
AZN
AstraZeneca PLC
|
$12.2B | $2B | 9.88% | 17.77% | 14.07% | $2B |
|
GSK
GSK PLC
|
$7.1B | $2.8B | 8.51% | 19.22% | 8.71% | $1.5B |
|
PFE
Pfizer
|
$11.9B | $3.2B | 5.09% | 8.91% | 4.1% | $5.8B |
|
SNN
Smith & Nephew PLC
|
-- | -- | 4.91% | 7.88% | -- | -- |
Haleon PLC vs. Competitors
-
Which has Higher Returns HLN or ADAP?
Adaptimmune Therapeutics PLC has a net margin of 8.37% compared to Haleon PLC's net margin of -2303.38%. Haleon PLC's return on equity of 8.91% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About HLN or ADAP?
Haleon PLC has a consensus price target of $10.71, signalling upside risk potential of 11.19%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 693.61%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Haleon PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 2 0 ADAPAdaptimmune Therapeutics PLC2 2 0 -
Is HLN or ADAP More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.845, suggesting its more volatile than the S&P 500 by 184.488%.
-
Which is a Better Dividend Stock HLN or ADAP?
Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.64%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or ADAP?
Haleon PLC quarterly revenues are $3.5B, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Haleon PLC's net income of $295.8M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Haleon PLC's price-to-earnings ratio is 23.94x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus 0.31x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.08x 23.94x $3.5B $295.8M ADAPAdaptimmune Therapeutics PLC0.31x -- $3.2M -$74.2M
-
Which has Higher Returns HLN or AZN?
AstraZeneca PLC has a net margin of 8.37% compared to Haleon PLC's net margin of 10.07%. Haleon PLC's return on equity of 8.91% beat AstraZeneca PLC's return on equity of 17.77%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B AZNAstraZeneca PLC81.7% $0.48 $69.5B -
What do Analysts Say About HLN or AZN?
Haleon PLC has a consensus price target of $10.71, signalling upside risk potential of 11.19%. On the other hand AstraZeneca PLC has an analysts' consensus of $85.68 which suggests that it could grow by 32.09%. Given that AstraZeneca PLC has higher upside potential than Haleon PLC, analysts believe AstraZeneca PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 2 0 AZNAstraZeneca PLC6 1 0 -
Is HLN or AZN More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.487%.
-
Which is a Better Dividend Stock HLN or AZN?
Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.64%. AstraZeneca PLC offers a yield of 2.39% to investors and pays a quarterly dividend of $1.05 per share. Haleon PLC pays 39.53% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or AZN?
Haleon PLC quarterly revenues are $3.5B, which are smaller than AstraZeneca PLC quarterly revenues of $14.9B. Haleon PLC's net income of $295.8M is lower than AstraZeneca PLC's net income of $1.5B. Notably, Haleon PLC's price-to-earnings ratio is 23.94x while AstraZeneca PLC's PE ratio is 28.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus 3.75x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.08x 23.94x $3.5B $295.8M AZNAstraZeneca PLC3.75x 28.77x $14.9B $1.5B
-
Which has Higher Returns HLN or GSK?
GSK PLC has a net margin of 8.37% compared to Haleon PLC's net margin of 5.1%. Haleon PLC's return on equity of 8.91% beat GSK PLC's return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B GSKGSK PLC68.47% $0.26 $36.4B -
What do Analysts Say About HLN or GSK?
Haleon PLC has a consensus price target of $10.71, signalling upside risk potential of 11.19%. On the other hand GSK PLC has an analysts' consensus of $43.55 which suggests that it could grow by 29.6%. Given that GSK PLC has higher upside potential than Haleon PLC, analysts believe GSK PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 2 0 GSKGSK PLC2 3 1 -
Is HLN or GSK More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.135%.
-
Which is a Better Dividend Stock HLN or GSK?
Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.64%. GSK PLC offers a yield of 4.63% to investors and pays a quarterly dividend of $0.40 per share. Haleon PLC pays 39.53% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or GSK?
Haleon PLC quarterly revenues are $3.5B, which are smaller than GSK PLC quarterly revenues of $10.4B. Haleon PLC's net income of $295.8M is lower than GSK PLC's net income of $530.1M. Notably, Haleon PLC's price-to-earnings ratio is 23.94x while GSK PLC's PE ratio is 21.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus 1.73x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.08x 23.94x $3.5B $295.8M GSKGSK PLC1.73x 21.22x $10.4B $530.1M
-
Which has Higher Returns HLN or PFE?
Pfizer has a net margin of 8.37% compared to Haleon PLC's net margin of 2.31%. Haleon PLC's return on equity of 8.91% beat Pfizer's return on equity of 8.91%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B PFEPfizer66.74% $0.07 $152.1B -
What do Analysts Say About HLN or PFE?
Haleon PLC has a consensus price target of $10.71, signalling upside risk potential of 11.19%. On the other hand Pfizer has an analysts' consensus of $30.73 which suggests that it could grow by 42.36%. Given that Pfizer has higher upside potential than Haleon PLC, analysts believe Pfizer is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 2 0 PFEPfizer6 14 1 -
Is HLN or PFE More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.
-
Which is a Better Dividend Stock HLN or PFE?
Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.64%. Pfizer offers a yield of 7.83% to investors and pays a quarterly dividend of $0.43 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.
-
Which has Better Financial Ratios HLN or PFE?
Haleon PLC quarterly revenues are $3.5B, which are smaller than Pfizer quarterly revenues of $17.8B. Haleon PLC's net income of $295.8M is lower than Pfizer's net income of $410M. Notably, Haleon PLC's price-to-earnings ratio is 23.94x while Pfizer's PE ratio is 15.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus 1.93x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.08x 23.94x $3.5B $295.8M PFEPfizer1.93x 15.31x $17.8B $410M
-
Which has Higher Returns HLN or SNN?
Smith & Nephew PLC has a net margin of 8.37% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 8.91% beat Smith & Nephew PLC's return on equity of 7.88%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B SNNSmith & Nephew PLC-- -- $8.4B -
What do Analysts Say About HLN or SNN?
Haleon PLC has a consensus price target of $10.71, signalling upside risk potential of 11.19%. On the other hand Smith & Nephew PLC has an analysts' consensus of $32.14 which suggests that it could grow by 28.31%. Given that Smith & Nephew PLC has higher upside potential than Haleon PLC, analysts believe Smith & Nephew PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 2 0 SNNSmith & Nephew PLC3 2 0 -
Is HLN or SNN More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Smith & Nephew PLC has a beta of 0.714, suggesting its less volatile than the S&P 500 by 28.646%.
-
Which is a Better Dividend Stock HLN or SNN?
Haleon PLC has a quarterly dividend of $0.05 per share corresponding to a yield of 1.64%. Smith & Nephew PLC offers a yield of 2.99% to investors and pays a quarterly dividend of $0.46 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Smith & Nephew PLC pays out 79.37% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or SNN?
Haleon PLC quarterly revenues are $3.5B, which are larger than Smith & Nephew PLC quarterly revenues of --. Haleon PLC's net income of $295.8M is higher than Smith & Nephew PLC's net income of --. Notably, Haleon PLC's price-to-earnings ratio is 23.94x while Smith & Nephew PLC's PE ratio is 26.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.08x versus 1.89x for Smith & Nephew PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.08x 23.94x $3.5B $295.8M SNNSmith & Nephew PLC1.89x 26.65x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Chewy a Growth Stock to Buy?
It might be a surprise to learn that during the…
Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 31x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Sell
11
CRL alert for Apr 11
Charles River Laboratories International [CRL] is down 0.2% over the past day.
Buy
77
DPST alert for Apr 11
Direxion Daily Regional Banks Bull 3X Shares [DPST] is down 0.79% over the past day.
Sell
35
KMX alert for Apr 11
CarMax [KMX] is up 2.87% over the past day.
